BioSpace News Archive

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results.

Telix Pharmaceuticals Limited announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC for highly pure no-carrier-added lutetium-177, a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation investigational products.

DexCom, Inc. reported its financial results as of and for the quarter and fiscal year ended December 31, 2021.

Baxter International Inc., a global medtech leader, will present at Citi’s 2022 Virtual Healthcare Conference on Wednesday, February 23, 2022.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter 2021 and year end 2021 financial results on Wednesday, February 23, 2022, before the open of the US financial markets.

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2021, and highlighted recent corporate progress.

VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system (CNS) disorders, today reported results for its third fiscal quarter ended December 31, 2021 and provided a corporate update.

A high dose of famotidine, commonly known as Pepcid, was found to have beneficial effects in adult patients with coronavirus disease 2019 (COVID-19), according to results of an outpatient clinical trial.

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, announced financial results for the fourth quarter and year ended December 31, 2021.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2021 financial results after market close on Thursday, March 3, 2022.